Henry Schein (NASDAQ:HSIC) CEO Thomas Popeck Sells 1,355 Shares

Henry Schein, Inc. (NASDAQ:HSIC) CEO Thomas Popeck sold 1,355 shares of the business’s stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $72.79, for a total transaction of $98,630.45. Following the sale, the chief executive officer directly owned 86,182 shares in the company, valued at approximately $6,273,187.78. The trade was a 1.55% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Henry Schein Stock Down 0.6%

Shares of HSIC opened at $72.24 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.76 and a current ratio of 1.38. Henry Schein, Inc. has a 52 week low of $60.56 and a 52 week high of $89.29. The stock has a market capitalization of $8.29 billion, a price-to-earnings ratio of 22.09, a PEG ratio of 2.15 and a beta of 0.88. The stock has a fifty day moving average of $77.72 and a 200-day moving average of $72.98.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, February 24th. The company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.30 by $0.04. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.The business had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.34 billion. During the same quarter in the previous year, the company posted $1.19 EPS. Henry Schein’s quarterly revenue was up 7.7% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, sell-side analysts anticipate that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

Institutional Trading of Henry Schein

A number of large investors have recently bought and sold shares of HSIC. CYBER HORNET ETFs LLC bought a new position in shares of Henry Schein in the 2nd quarter worth about $25,000. MUFG Securities EMEA plc bought a new stake in shares of Henry Schein during the 2nd quarter valued at about $27,000. Flagship Harbor Advisors LLC acquired a new stake in Henry Schein during the fourth quarter worth approximately $30,000. Federated Hermes Inc. bought a new stake in Henry Schein in the fourth quarter worth approximately $32,000. Finally, Los Angeles Capital Management LLC bought a new stake in Henry Schein in the fourth quarter worth approximately $37,000. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Key Henry Schein News

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Zacks raised its Q4 2027 EPS estimate to $1.62 from $1.44, signaling stronger expected back‑half performance for FY2027. Zacks note
• Positive Sentiment: Zacks boosted its Q3 2027 EPS to $1.49 from $1.42 and lifted FY2027 to $5.76 from $5.68, implying improved full‑year outlook beyond FY2026. Zacks note
• Positive Sentiment: Zacks nudged FY2026 guidance upward to $5.26 from $5.23 and raised Q3 2026 to $1.43 (from $1.39) and Q4 2026 to $1.44 (from $1.43), reflecting incremental improvement to near‑term full‑year estimates. Zacks note
• Neutral Sentiment: Zacks published an FY2028 EPS projection of $6.28 (new/forward‑looking estimate). This provides a growth runway but is not a direct revision to consensus today. Zacks note
• Negative Sentiment: Zacks cut its Q2 2027 EPS forecast to $1.38 from $1.47, a notable downgrade for the mid‑year quarter that may pressure near‑term expectations. Zacks note
• Negative Sentiment: Zacks trimmed Q1 2027 to $1.28 from $1.35 and lowered Q1 2026 to $1.20 from $1.22, indicating weaker near‑term quarterly visibility. Zacks note

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Morgan Stanley upped their price objective on Henry Schein from $58.00 to $61.00 and gave the company an “underweight” rating in a research note on Wednesday, February 25th. Weiss Ratings reissued a “hold (c)” rating on shares of Henry Schein in a report on Monday, December 29th. Barrington Research set a $97.00 price target on shares of Henry Schein and gave the company an “outperform” rating in a research report on Wednesday, February 25th. UBS Group raised their price target on shares of Henry Schein from $79.00 to $87.00 and gave the company a “neutral” rating in a research note on Wednesday, February 25th. Finally, Mizuho lifted their price target on shares of Henry Schein from $81.00 to $88.00 and gave the stock a “neutral” rating in a report on Wednesday, February 25th. Six research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $85.58.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.